AccScience Publishing / JCBP / Volume 1 / Issue 1 / DOI: 10.36922/jcbp.0571
Cite this article
Journal Browser
Volume | Year
News and Announcements
View All

A higher risk for melanoma in patients with Parkinson’s disease: Based on the results from National Health and Nutrition Examination Survey 2001 – 2004

Huan Chen1 Ning Du2 Lixia Wang3* Lin Yang3*
Show Less
1 Department of Dermatology, The First Affiliated Hospital of Dali University, Dali, Yunnan, China
2 Department of Psychiatry, University-Town Hospital of Chongqing Medical University, Chongqing, China
3 Department of Neurology, The First Affiliated Hospital of Dali University, Dali, Yunnan, China
Submitted: 18 April 2023 | Accepted: 30 May 2023 | Published: 26 June 2023
© 2023 by the Author(s). Licensee AccScience Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( )

The relationship between Parkinson’s disease (PD) and melanoma has been controversial. The present study used data from the 2001 – 2004 National Health and Nutrition Examination Survey database. This study included individuals aged ≥20 years with complete data on PD and melanoma, in which 48 participants were comorbid with the melanoma group, and 5774 were not. Both univariate and multivariate logistic regression analyses were conducted to investigate the connection. There was a higher proportion of PD in the melanoma group than in the non-melanoma group (2.45% vs. 0.30%). Univariate logistic regression analysis revealed that individuals with PD had an 8.32-fold higher risk of developing melanoma than those without PD. In addition, PD was significantly correlated with melanoma (OR, 8.747; 95% CI, 1.264 – 60.506; p = 0.030) after controlling for covariates in multivariate analysis. In conclusion, our research indicates a significant correlation between PD and melanoma in American adults.

Parkinson’s disease
National Health and Nutrition Examination Survey
Sampling weights
Science and Technology Plan of Yunnan Provincial Department of Science and Technology
  1. Siegel RL, Miller KD, Jemal A, 2019, Cancer statistics, 2019. CA Cancer J Clin, 69: 7 – 34.


  1. Lyakhov PA, Lyakhova UA, Nagornov NN, 2022, System for the recognizing of pigmented skin lesions with fusion and analysis of heterogeneous data based on a multimodal neural network. Cancers (Basel), 14: 1819.


  1. Brot S, Thamrin NP, Bonnet ML, et al., 2022, Long-term evaluation of intranigral transplantation of human iPSC derived dopamine neurons in a Parkinson’s disease mouse model. Cells, 11: 1596.


  1. Gao H, Sun H, Yan N, et al., 2022, ATP13A2 declines zinc induced accumulation of α-synuclein in a Parkinson’s disease model. Int J Mol Sci, 23: 8035.


  1. Skibba JL, Pinckley J, Gilbert EF, et al., 1972, Multiple primary melanoma following administration of levodopa. Arch Pathol, 93: 556 – 561.


  1. Bliss JM, Ford D, Swerdlow AJ, et al., 1995, Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: Systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE). Int J Cancer, 62: 367 – 376.


  1. Dong J, Gao J, Nalls M, et al., 2014, Susceptibility loci for pigmentation and melanoma in relation to Parkinson’s disease. Neurobiol Aging, 35: 1512.e5 – 1512.e10.


  1. Gao X, Simon KC, Han J, et al., 2009, Genetic determinants of hair color and Parkinson’s disease risk. Ann Neurol, 65: 76 – 82.


  1. Liu R, Gao X, Lu Y, et al., 2011, Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology, 76: 2002 – 2009.


  1. Devine MJ, Plun-Favreau H, Wood NW, 2011, Parkinson’s disease and cancer: Two wars, one front. Nat Rev Cancer, 11: 812 – 823.


  1. Law MH, Bishop DT, Lee JE, et al., 2015, Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. Nat Genet, 47: 987 – 995.


  1. Chen X, Chen H, Cai W, et al., 2017, The melanoma-linked “redhead” MC1R influences dopaminergic neuron survival. Ann Neurol, 81: 395 – 406.


  1. Bose A, Petsko GA, Eliezer D, 2018, Parkinson’s disease and melanoma: Co-occurrence and mechanisms. J Parkinsons Dis, 8: 385 – 398.


  1. Dean DN, Lee JC, 2020, Defining an amyloid link between Parkinson’s disease and melanoma. Proc Natl Acad Sci U S A, 117: 22671 – 22673.


  1. Xu S, Chan P, 2015, Interaction between neuromelanin and alpha-synuclein in Parkinson’s disease. Biomolecules, 5: 1122 – 1142.


  1. Hu HH, Kannengiesser C, Lesage S, et al., 2016, Parkin inactivation links Parkinson’s disease to melanoma. J Natl Cancer Inst, 108: djv340.


  1. Alvarez-Erviti L, Rodriguez-Oroz MC, Cooper JM, et al., 2010, Chaperone-mediated autophagy markers in Parkinson disease brains. Arch Neurol, 67: 1464 – 1472.


  1. Rubinsztein DC, 2006, The roles of intracellular protein-degradation pathways in neurodegeneration. Nature, 443: 780 – 786.


  1. Pan T, Kondo S, Le W, et al., 2008, The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson’s disease. Brain, 131: 1969 – 1978.


  1. Duffy DL, Zhao ZZ, Sturm RA, et al., 2010, Multiple pigmentation gene polymorphisms account for a substantial proportion of risk of cutaneous malignant melanoma. J Invest Dermatol, 130: 520 – 528.


  1. Halaban R, Cheng E, Zhang Y, et al., 1997, Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells. Proc Natl Acad Sci U S A, 94: 6210 – 6215.


22. Gudbjartsson DF, Sulem P, Stacey SN, et al., 2008, ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet, 40: 886 – 891.

Conflict of interest
The authors have no conflicts of interest to declare.
Back to top
Journal of Clinical and Basic Psychosomatics, Electronic ISSN: 2972-4414 Print ISSN: TBA, Published by AccScience Publishing